News Channels

11 Feb 2019 UCB and Epilepsy Society announce pioneering UK Genomics R&D collaboration
11 Feb 2019 Samsung Bioepis and C-Bridge Capital to Develop and Commercialize Next-Generation Biosimilars in China
10 Feb 2019 One-Year Results from Positive Phase 3 EYLEA Trial in Diabetic Retinopathy Presented at Angiogenesis Symposium
09 Feb 2019 Finch Therapeutics’ Investigational Drug CP101 Granted Breakthrough Therapy Designation from FDA for Recurrent C. Difficile Infection
09 Feb 2019 NuvOx Pharma’s NVX-208 Shows Positive Results in Phase Ib/II Stroke Trial
09 Feb 2019 uniQure Announces Updated Clinical Data from Phase IIb Study of AMT-061 in Patients with Hemophilia B
07 Feb 2019 Sangamo Announces Interim Results Of Phase 1/2 CHAMPIONS Study Showing Preliminary Evidence Of In Vivo Genome Editing In Patients With MPS II Treated With SB-913
07 Feb 2019 Results on Efficacy of PMZ-1620, an Endothelin-B Agonist, from Ongoing Phase II Trial in Patients with Cerebral Ischemic Stroke Presented at International Stroke Conference 2019
07 Feb 2019 Sangamo Announces Interim Results Of Phase 1/2 EMPOWERS Study Evaluating SB-318 Zinc Finger Nuclease (ZFN) In Vivo Genome Editing Demonstrating Increased Leukocyte IDUA Activity In Patients With MPS I
07 Feb 2019 Antidote Therapeutics Announces Collaboration with National Cancer Institute to Develop ATI-1013, a Novel Nicotine-Binding Antibody, for Reducing Lung Cancer in High Risk Smokers
07 Feb 2019 Neurogene Announces Presentation of Preclinical Data for Gene Therapies to Treat AGU and CMT4J, Two Rare and Devastating Neurodegenerative Disorders
07 Feb 2019 Medicenna Presents Promising Clinical Data from Phase 2b Recurrent Glioblastoma Trial of MDNA55
07 Feb 2019 Solid Biosciences Announces Preliminary SGT-001 Data and Intention to Dose Escalate in IGNITE DMD Clinical Trial for Duchenne Muscular Dystrophy
07 Feb 2019 Arch Oncology Announces First Patient Dosed in Phase 1 Clinical Trial of AO-176, an Anti-CD47 Antibody with a Best-in-Class Profile
07 Feb 2019 AVROBIO, Inc. Announces Updated Clinical Data from Ongoing Phase 1 and Phase 2 Studies for AVR-RD-01 Gene Therapy for Fabry Disease
07 Feb 2019 Innovent Receives IND Approval of a Bispecific Antibody (IBI318) by the NMPA
07 Feb 2019 Evotec and Galapagos enter into collaboration in the field of fibrosis
06 Feb 2019 FDA approves Cablivi® (caplacizumab-yhdp), the first Nanobody®-based medicine, for adults with acquired thrombotic thrombocytopenic purpura (aTTP)FDA approves Cablivi® (caplacizumab-yhdp), the first Nanobody®-based medicine, for adults with acquired throm
06 Feb 2019 Moderna Announces Dosing of the First Monoclonal Antibody Encoded by mRNA in a Clinical Trial
06 Feb 2019 Orphan Technologies Announces First Patients Treated in Phase 1/2 Trial of OT-58 in Homocystinuria

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2017 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up